These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8825847)

  • 1. Adverse effects of intravenous immunoglobulin therapy.
    Ryan ME; Webster ML; Statler JD
    Clin Pediatr (Phila); 1996 Jan; 35(1):23-31. PubMed ID: 8825847
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012.
    Robert P; Hotchko M
    Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899
    [No Abstract]   [Full Text] [Related]  

  • 3. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
    Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD
    Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment and management of primary antibody deficiency.
    Empson M; Sinclair J; O'Donnell J; Ameratunga R; Fitzharris P; Steele R;
    N Z Med J; 2004 Jun; 117(1195):U914. PubMed ID: 15282626
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A; Marai I; Appel S; Zimlichman E
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giving intravenous immunoglobulin.
    Scherf R; White-Reid K
    RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.
    Spurlock NK; Prittie JE
    J Vet Emerg Crit Care (San Antonio); 2011 Oct; 21(5):471-83. PubMed ID: 22316195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between IGIV products: impact on clinical outcome.
    Gelfand EW
    Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of intravenous immune globulin treatment in neurologic disease.
    Achiron A
    Neurology; 1997 Sep; 49(3):899-900. PubMed ID: 9305372
    [No Abstract]   [Full Text] [Related]  

  • 10. Review: intravenous immunoglobulin therapy and thromboembolic complications.
    Katz U; Shoenfeld Y
    Lupus; 2005; 14(10):802-8. PubMed ID: 16302674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein-losing enteropathy after the total cavopulmonary connection: impact of intravenous immunoglobulin.
    Zaupper LB; Nielsen BW; Herlin T
    Congenit Heart Dis; 2011; 6(6):624-9. PubMed ID: 22010984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of intravenous immunoglobulin preparations.
    Weisman LE
    Isr J Med Sci; 1994; 30(5-6):459-63. PubMed ID: 8034504
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
    Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis.
    Baruteau J; Heissat S; Broué P; Collardeau-Frachon S; Bouvier R; Fabre M; Debiec H; Ronco P; Uzan M; Narcy P; Cordier MP; Lachaux A; Lamireau T; Elleau C; Filet JP; Mitanchez D; Dupuy MP; Salaün JF; Odent S; Davison J; Debray D; Guigonis V
    J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):629-35. PubMed ID: 25079484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5th International symposium on IVIG: IVIG in the third millenium, 25-27 September 2003, Interlaken, Switzerland.
    Shoenfeld Y
    Autoimmun Rev; 2004 Mar; 3(3):234-41. PubMed ID: 15110237
    [No Abstract]   [Full Text] [Related]  

  • 17. Human immunoglobulin and the Guillain-Barre syndrome: new indication. An alternative to plasmapheresis.
    Prescrire Int; 2000 Oct; 9(49):142-3. PubMed ID: 11603414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with intravenous immunoglobulin in neurological diseases. A descriptive study of effects seen from the patient's and health services' perspectives].
    Wintzell A; Eriksson T; Lundgren A; Petersson J
    Lakartidningen; 2008 May 21-27; 105(21):1571-5. PubMed ID: 18574994
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous immunoglobulins as treatment of severe cutaneous polyarteritis nodosa.
    Marie I; Miranda S; Girszyn N; Soubrane JC; Vandhuick T; Levesque H
    Intern Med J; 2012 Apr; 42(4):459-62. PubMed ID: 22498120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma.
    Ihn H; Mimura Y; Yazawa N; Jinnin M; Asano Y; Yamane K; Tamaki K
    Br J Dermatol; 2007 May; 156(5):1058-60. PubMed ID: 17381465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.